Montanova Capital LLC Has $48.59 Million Holdings in Replimune Group, Inc. $REPL

Montanova Capital LLC grew its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 4.0% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 4,389,836 shares of the company’s stock after buying an additional 168,000 shares during the quarter. Montanova Capital LLC’s holdings in Replimune Group were worth $48,595,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of REPL. International Assets Investment Management LLC acquired a new position in shares of Replimune Group in the 4th quarter worth approximately $29,000. CWM LLC increased its holdings in Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after purchasing an additional 2,886 shares in the last quarter. Allworth Financial LP acquired a new stake in Replimune Group during the 2nd quarter valued at $62,000. Essential Partners LLC raised its position in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of Replimune Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the transaction, the insider directly owned 224,215 shares in the company, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the transaction, the chief accounting officer owned 99,425 shares of the company’s stock, valued at $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 79,124 shares of company stock valued at $1,038,364. Insiders own 5.40% of the company’s stock.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $15.30 on Tuesday. The firm has a fifty day moving average of $11.92 and a two-hundred day moving average of $8.40. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -4.86 and a beta of 0.88. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $16.15.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, equities research analysts predict that Replimune Group, Inc. will post -2.81 EPS for the current year.

Analyst Ratings Changes

REPL has been the topic of several research analyst reports. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $11.00 to $17.00 in a report on Tuesday, August 4th. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Friday, August 7th. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Tuesday, June 30th. Finally, Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.